Risk, Risk Factors, and Surveillance of Subsequent Malignant Neoplasms in Survivors of Childhood Cancer: A Review

• Published in: Journal of clinical oncology Vol. 36; no. 21; pp. 2145 - 2152
• Main Authors: Turcotte, Lucie M., Neglia, Joseph P., Reulen, Raoul C., Ronckers, Cecile M., van Leeuwen, Flora E., Morton, Lindsay M., Hodgson, David C., Yasui, Yutaka, Oeffinger, Kevin C., Henderson, Tara O.
• Format: Journal Article
• Language: English
• Published: United States American Society of Clinical Oncology 20.07.2018
• Subjects: Cancer Survivors - statistics & numerical data; Child; Cohort Studies; Humans; Incidence; Neoplasms, Second Primary - diagnosis; Neoplasms, Second Primary - epidemiology; Risk; Risk Factors; SPECIAL SERIES
• ISSN: 0732-183X; 1527-7755; 1527-7755
• DOI: 10.1200/JCO.2017.76.7764

Subsequent malignant neoplasms (SMNs) in childhood cancer survivors cause substantial morbidity and mortality. This review summarizes recent literature on SMN epidemiology, risk factors, surveillance, and interventions. Survivors of childhood cancer experience long-term increased SMN risk compared with the general population, with a greater than twofold increased solid tumor risk extending beyond age 40 years. There is a dose-dependent increased risk for solid tumors after radiotherapy, with the highest risks for tumors occurring in or near the treatment field (eg, greater than fivefold increased risk for breast, brain, thyroid, skin, bone, and soft tissue malignancies). Alkylating and anthracycline chemotherapies increase the risk for development of several solid malignancies in addition to acute leukemia/myelodysplasia, and these risks may be modified by other patient characteristics, such as age at exposure and, potentially, inherited genetic susceptibility. Strategies for identifying survivors at risk and initiating long-term surveillance have improved and interventions are underway to improve knowledge about late-treatment effects among survivors and caregivers. Better understanding of treatment-related risk factors and genetic susceptibility holds promise for refining surveillance strategies and, ultimately, upfront cancer therapies.